High-resolution microscopic visualization of a coronavirus particle highlighting intricate RNA and protein structures.
Image Credit: Scientific Frontline / AI generated
Scientific Frontline: Extended "At a Glance" Summary: Coronavirus RNA-Protein Interactions
The Core Concept: Researchers have mapped the intricate interactions between viral RNA and the proteins responsible for coronavirus replication and regulation. By identifying these highly conserved RNA binding sites, scientists have uncovered new fundamental molecular targets for variant-resistant antiviral treatments.
Key Distinction/Mechanism: Unlike current treatments that target highly mutable viral features, this approach uses enhanced cross-linking and immunoprecipitation (eCLIP) to map the entire viral genome. It targets essential, underlying molecular machinery that is conserved across coronavirus species, making it exceedingly difficult for the virus to evade the therapy through mutation.
Major Frameworks/Components:
- Enhanced cross-linking and immunoprecipitation (eCLIP): A genome-scale mapping technique used to survey and identify unexpected RNA-protein interaction sites across the entire viral genome.
- Target proteins: The research identified critical RNA binding sites for primase cofactor (NSP8), RNA-dependent RNA polymerase (NSP12), and the nucleocapsid (N) protein.
- The 5′ untranslated region: A complex RNA structure at the beginning of the genome that interacts with the N protein to regulate translation.
- Locked nucleic acids (LNAs): Short, modified nucleic acid sequences deployed to bind specific RNA regions, successfully blocking protein interactions and significantly reducing viral replication in animal cells and human lung cells.
Branches of Science: Molecular Virology, Structural Biology, Molecular Genetics, and Pharmacology.
Future Application: This research establishes a foundation for developing broad-spectrum antiviral drugs capable of treating multiple coronavirus species. By deploying targeted therapies like LNAs, medicine could preemptively address future zoonotic outbreaks before they escalate into pandemics.
Why It Matters: Because coronaviruses evolve rapidly, therapies targeting conserved RNA-protein interactions maintain long-term efficacy, preventing the drug resistance that frequently undermines conventional, variant-specific antiviral treatments.
A study led by researchers at the University of California San Diego School of Medicine and the University of California, Riverside (UCR), School of Medicine has identified new targets for antiviral drugs against coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. These new targets could help scientists discover treatments that are less vulnerable to the rapid evolution of these viruses.
“There’s so much we don’t know about coronaviruses at a fundamental biological level, and everything we learn gives us more options when developing treatments,” said senior study author Gene Yeo, PhD, professor of cellular and molecular medicine at the UC San Diego School of Medicine, director of the Center for RNA Technologies and Therapeutics, and director of the Sanford Stem Cell Innovation Center. “If we want to stay ahead of these viruses, we have to understand them from the inside out.”
The research, published in Nature Communications, mapped previously unknown interactions between the RNA that makes up the SARS-CoV-2 genome and proteins involved in the virus’s replication and regulation. The team identified specific RNA binding sites for three proteins—primase cofactor (NSP8), RNA-dependent RNA polymerase (NSP12), and nucleocapsid (N)—and found that disrupting these interactions significantly reduced viral replication.
The results offer an early proof of concept for targeting RNA-protein interactions as a treatment strategy for diseases caused by coronaviruses, including COVID-19.
“SARS-CoV-2 evolves very quickly, so it’s important to understand the really basic and essential machinery of the virus,” said Joy Xiang, PhD, assistant professor of biomedical sciences at the UCR School of Medicine. “If we target something essential that the virus depends on to function and can’t easily change, the virus is less likely to evolve away from it, which would lead to drug resistance.”
Current antiviral drugs already illustrate the value of targeting essential viral machinery. Remdesivir targets the enzyme that copies the virus’s RNA genome, while nirmatrelvir targets viral proteins involved in processing the long protein chains produced during infection.
The researchers used a technique known as enhanced cross-linking and immunoprecipitation, or eCLIP, to survey the viral genome and determine where viral proteins interact with RNA. Rather than examining only regions previously predicted to be important, this approach allowed the researchers to map interactions across the entire genome and identify unexpected sites.
One finding involved the N protein and a region at the beginning of the viral genome known as the 5′ untranslated region. This region contains a complex RNA structure that is present in many coronaviruses, but whose precise functions are not fully understood. The researchers found that its interaction with the N protein appears to regulate translation, an essential process in which RNA is used to make proteins.
The researchers also identified a previously unknown interaction involving NSP12 and the RNA encoding viral protein NSP3. This finding suggests that viral RNA may play regulatory roles beyond simply serving as a template for producing proteins.
“Viruses look simpler than humans at first glance, but there’s a lot of underlying complexity to their molecular biology we’re only just beginning to unravel,” said Yeo. “Our findings suggest that viral RNA may have a more significant role in regulating fundamental cellular processes than we previously understood.”
The researchers next tested whether the newly identified regions could be disrupted using locked nucleic acids (LNAs)—short, modified nucleic acid sequences designed to bind specific regions of RNA, blocking these regions from interacting with proteins. Blocking the interaction sites significantly reduced viral replication in animal cells.
The team found similar results in human lung cells, providing additional evidence that the interactions could be relevant to human infection. Their findings suggest that targeting conserved viral processes can work across diverse cells, organs, and host organisms, which is a crucial factor in preparing for future viral pandemics that often begin when a virus jumps from animals to humans.
The research also points toward the possibility of developing treatments that could work against multiple coronaviruses. Because some of the proteins and RNA sequences involved in these viral life cycle processes are conserved among coronaviruses, targeting them could be less dependent on the emergence of individual viral variants.
“The goal is to understand these core interactions so that, eventually, drug developers can develop therapies that specifically target them,” Xiang said.
According to the researchers, the broader significance of the research also extends beyond COVID-19 and the development of a single drug.
“We need to understand the fundamental biology of these viruses instead of just being reactive to outbreaks,” Xiang said. “There’s value in studying these biological differences, because that understanding can give us new opportunities to develop better treatments.”
Funding: The work has been supported by Emergency COVID-19 Research Seed Funding (#R00RG2636) from the University of California Office of the President. Publication includes data generated at the UC San Diego IGM Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased with funding from a National Institutes of Health SIG grant (#S10 OD026929). AFC is supported by an NIH grant K08 AI130381 and a Burroughs Wellcome Fund Career Award for Medical Scientists.
Published in journal: Nature Communications
Authors: Joy S. Xiang, Karen X. Zhao, Laliv Tadri, Kurt Tamaru, Brian A. Yee, Katherine Rothamel, Jonathan C. Schmok, Jasmine R. Mueller, Samuel S. Park, Assael A. Madrigal, Rachael N. McVicar, Elizabeth M. Kwong, Ben A. Croker, Alex E. Clark, Aaron F. Carlin, Charly Acevedo, Declan F. McCole, Seán E. O’Leary, Rong Hai, Sandra L. Leibel, and Gene W. Yeo
Source/Credit: University of California San Diego | Miles Martin
Edited by: Scientific Frontline
Reference Number: vi110226_01
